Sanofi: positive phase III data in myeloma
According to these data, Sarclisa, in combination with bortezomib, lenalidomide and dexamethasone (VRd), followed by the Sarclisa-Rd combination, reduced the risk of relapse or death by 40%, compared with the VRd protocol, followed by the Rd combination.
The primary endpoint, progression-free survival, was thus achieved. All data are published simultaneously in the NEJM and form the basis for regulatory submissions.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction